Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
3 reports, 3 independent
Updated Jul 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.Sub-event
Cristian Massacesi joins BMS as CMO, having previously worked at AstraZeneca.1 source
Keep exploring
The entities involved
-
Karuna Therapeutics
biopharmaceutical company
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- BioPharma DiveBristol Myers shuffles its executive ranks with new CMO This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newslette
- Business WireCristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development Dr. Massacesi will join BMS August 1 and serve on the Executive Leaders